laquinimod

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The phase III placebo-controlled BRAVO study assessed laquinimod effects in patients with relapsing-remitting MS (RRMS), and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
BACKGROUND There are two generally accepted strategies for treating multiple sclerosis (MS), preventing central nervous system… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 3
Is this relevant?
2012
2012
Proinflammatory circulating monocytes have important roles in the pathology of multiple sclerosis (MS) and its animal model… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Laquinimod is a promising, orally available compound that has been successfully evaluated in placebo-controlled phase II/III… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Laquinimod is a small, novel, orally active, well-tolerated molecule that significantly reduced gadolinium-enhancing lesions in… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND A 24-week phase II trial has shown that 0.3 mg of laquinimod given daily to patients with relapsing-remitting multiple… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Laquinimod is a novel immunomodulatory substance developed as an orally available disease modifying treatment in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The new orally active drug laquinimod (ABR-215062) was evaluated in experimental autoimmune encephalomyelitis (EAE) in the Lewis… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
A new orally active drug, laquinimod (ABR-215062), was shown to completely inhibit the development of murine acute experimental… (More)
Is this relevant?